Ernexa (ERNA) Director Elena Ratner Receives 5,944-Share Option Award

What Happened
Elena Ratner, a director of Ernexa Therapeutics, was granted a derivative award (reported as a stock option) covering 5,944 shares on 2026-08-31. The acquisition price is reported as $0.00 (no cash paid at grant), and the filing records the transaction as an award rather than a purchase or sale.

Key Details

• Transaction date: 2026-08-31; Form 4 filed 2026-09-01 (filed the next day).
• Instrument and amount: Derivative award / stock option for 5,944 shares; acquisition price shown as $0.00.
• Shares owned after transaction: Not specified in the filing.
• Vesting (footnote): Subject to continued service — one-third vests on the first anniversary of the grant date, with the remaining shares vesting in 24 substantially equal monthly installments thereafter.
• No 10b5-1 plan, tax-withholding sale, or late-filing indication was disclosed in the provided details.

Context
This was a time‑based option award to a board member, not an open‑market purchase or sale. Such grants are common as director compensation and do not represent an immediate cash transaction or realized gain until options are exercised and/or shares sold.